Literature DB >> 15937367

Dengue vaccines: problems and prospects.

U C Chaturvedi1, Richa Shrivastava, Rachna Nagar.   

Abstract

The extent of cumulative disease burden caused by dengue virus has attained an unprecedented level in recent times with sharp increase in the size of human population at risk. Dengue disease presents highly complex medical, economic and ecologic problems. The surge in publications on the development of dengue vaccines, taking advantage of new generation of biotechnology techniques indicates the profound interest and urgency in the scientific and medical communities in combating this disease. This review summarizes the importance of critical subjects like pathogenesis of dengue haemorrhagic fever and inadequacy of animal model that have adversely affected dengue vaccine development. Further, the remarkable progresses so far made in dengue vaccine research not only employing a diverse range of new strategies but also re-using old techniques to improve the existing vaccines, have been presented. The efficacy and safety of some of the new vaccine candidates have been evaluated and proven in human preclinical/clinical trials. Besides the technical advancement in vaccine development, vaccine safety and vaccine formulation have been examined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937367

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  16 in total

1.  Mouse STAT2 restricts early dengue virus replication.

Authors:  Joseph Ashour; Juliet Morrison; Maudry Laurent-Rolle; Alan Belicha-Villanueva; Courtney Ray Plumlee; Dabeiba Bernal-Rubio; Katherine L Williams; Eva Harris; Ana Fernandez-Sesma; Christian Schindler; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

2.  Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines.

Authors:  Raja Mazumder; Zhang-Zhi Hu; C R Vinayaka; Jose-Luis Sagripanti; Simon D W Frost; Sergei L Kosakovsky Pond; Cathy H Wu
Journal:  Virus Genes       Date:  2007-05-17       Impact factor: 2.332

3.  NEUROLOGICAL INFECTIONS IN THE RETURNING INTERNATIONAL TRAVELER.

Authors:  May H Han; Melanie Walker; Joseph R Zunt
Journal:  Continuum (Minneap Minn)       Date:  2006-04

4.  Dengue Vaccine: The Current Status.

Authors:  M S Mustafa; V K Agrawal
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

Authors:  James S Testa; Vivekananda Shetty; Gomathinayagam Sinnathamby; Zacharie Nickens; Julie Hafner; Shivali Kamal; Xianchao Zhang; Marti Jett; Ramila Philip
Journal:  J Infect Dis       Date:  2012-01-13       Impact factor: 5.226

6.  Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.

Authors:  Mariel E Pérez-Vélez; Teresita García-Nieves; Candimar Colón-Sánchez; Idalí Martínez
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

7.  Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia.

Authors:  Ramapraba Appanna; Tan Lian Huat; Lucy Lum Chai See; Phoay Lay Tan; Jamuna Vadivelu; Shamala Devi
Journal:  Clin Vaccine Immunol       Date:  2007-06-13

Review 8.  Dengue and dengue haemorrhagic fever: Indian perspective.

Authors:  U C Chaturvedi; Rachna Nagar
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

9.  An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.

Authors:  Laura J White; Melissa M Parsons; Alan C Whitmore; Brandon M Williams; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

10.  Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.

Authors:  Charles E McGee; Konstantin Tsetsarkin; Dana L Vanlandingham; Kate L McElroy; Jean Lang; Bruno Guy; Thierry Decelle; Stephen Higgs
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.